Inhibikase Therapeutics, Inc. (NYSE:IKT) Expected to Earn Q2 2024 Earnings of ($0.58) Per Share
Inhibikase Therapeutics, Inc. (NYSE:IKT – Free Report) – Equities researchers at HC Wainwright dropped their Q2 2024 EPS estimates for Inhibikase Therapeutics in a note issued to investors on Tuesday, May 21st. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($0.58) for the quarter, down from their […]
More Stories
SecureWorks Corp. (NASDAQ:SCWX) Short Interest Down 33.4% in October
SecureWorks Corp. (NASDAQ:SCWX – Get Free Report) was the target of a significant drop in short interest in October. As...
SecureWorks Corp. (NASDAQ:SCWX) Short Interest Down 33.4% in October
SecureWorks Corp. (NASDAQ:SCWX – Get Free Report) was the target of a significant drop in short interest in October. As...
SLM Co. (NASDAQ:SLMBP) Short Interest Update
SLM Co. (NASDAQ:SLMBP – Get Free Report) was the recipient of a large drop in short interest in October. As...
SLM Co. (NASDAQ:SLMBP) Short Interest Update
SLM Co. (NASDAQ:SLMBP – Get Free Report) was the recipient of a large drop in short interest in October. As...
Short Interest in Red River Bancshares, Inc. (NASDAQ:RRBI) Rises By 46.1%
Red River Bancshares, Inc. (NASDAQ:RRBI – Get Free Report) was the recipient of a significant growth in short interest in...
Short Interest in Red River Bancshares, Inc. (NASDAQ:RRBI) Rises By 46.1%
Red River Bancshares, Inc. (NASDAQ:RRBI – Get Free Report) was the recipient of a significant growth in short interest in...